Europe's STOXX 600 struggled for direction on Tuesday as rising industrials and financial services shares offset losses in ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Insulin has long been the typical pharmacological go-to agent for gestational diabetes, the researchers pointed out, but oral ...

Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform.Don't Miss Our New Year's Offers:Discover the latest stocks ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, ...

Alex Brenchat, PhD, is VP and practice area lead for local pharmacovigilance services at PharmaLex. Brenchat has more than 20 ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

AIMRC & WECARE will host Juleen Zierath of the Karolinska Institute, Stockholm, at 12:55 p.m. Wednesday, Jan. 15, at the Jones Family Student-Athlete Success Center, room 104.